. Author manuscript; available in PMC: 2014 Oct 17.

Published in final edited form as: Drug Discov Today Dis Models. 2013 Jan 26;10(3):e145–e151. doi: 10.1016/j.ddmod.2012.11.003

Table 2.

Summary of currently used animal models of pulmonary fibrosis

Model	Administration	Advantages
Bleomycin	Intratracheal/pump/inhalation/intravenous (IV)/intraperitoneal (IP)	Most widely used model in literature
Silica	Intratracheal/inhalation	Persistent fibrosis and clinically relevant as a model for human silicosis
Fluorescein isothiocyanate (FITC)	Intratracheal/IV/IP	Persistent fibrosis, quick development of fibrosis and not mouse strain dependent
Radiation	Thoracic exposure	Clinically relevant as a model for pneumonitis and fibrosis
Viral vector delivery	Intratracheal/IV	Specific fibrosis-related genes
Transgenic models	Genetic engineering: pronuclear injection (PNI)/transgene insertion	Specific fibrosis-related genes